Latest Phenols Stories

NKTR-181 rates similar to placebo on "drug liking" and "feeling high" scores at all doses studied and differentiates from the widely abused drug oxycodone with high statistical significance (p

The patent covers the process and preparation of Tapentadol for the treatment of moderate to severe-acute pain NESS ZIONA, Israel, June 18, 2013 /PRNewswire/ -- Mapi Pharma Ltd. (Mapi), developer of complex bulk Active Pharmaceutical Ingredients (APIs), generic and innovative intermediates, and finished dosage forms based on selected drug delivery systems, announced today that the company has been granted a United States patent for Tapentadol. Tapentadol is indicated in the US...

The American Society of Addiction Medicine (ASAM) will release the most comprehensive report on the effectiveness of medications for opiate addiction and on the arbitrary restrictions on these FDA-approved drugs by many state governments and insurance companies. Safe and effective medications to treat opiate addiction are seriously under-utilized, resulting in preventable suffering and death. Washington (PRWEB) June 17, 2013 The American Society of Addiction Medicine (ASAM) will release...

New report shows increasing restrictions on addiction medications WASHINGTON, June 17, 2013 /PRNewswire-USNewswire/ -- The American Society of Addiction Medicine (ASAM) will release the most comprehensive report on the effectiveness of medications for opioid addiction and on the arbitrary restrictions on these FDA-approved drugs by many state governments and insurance companies. Drug overdoses now kill more Americans than drunk driving car crashes, an epidemic led by misuse of opioid...

MISSISSAUGA, ON, June 17, 2013 /CNW/ - A second analysis of data from real-world study PATHOS, recently published in the British Medical Journal, shows that treatment of chronic obstructive pulmonary disease (COPD) patients with SYMBICORT(®) (budesonide/formoterol) was associated with a lower incidence of pneumonia and pneumonia related death, compared to treatment of COPD patients with ADVAIR(®) (fluticasone/salmeterol).(i) PATHOS is the largest real-world study to compare the...

Composition of Matter Patent Provides Coverage Until 2031 SYDNEY and BEDMINSTER, N.J., June 12, 2013 /PRNewswire/ -- QRxPharma Limited (ASX: QRX and OTCQX: QRXPY) announced today that the United States Patent and Trademark Office (USPTO) issued the Company U.S. Patent #8,461,171 ("'171 patent") titled "Hybrid Opioid Compounds and Compositions," which expires in 2031. This patent covers a hybrid morphine-oxycodone molecule where these two different opioids are chemically linked. The...

PISGAH FOREST, N.C., June 12, 2013 /PRNewswire/ -- As controversy surrounds the recent FDA decisions concerning abuse deterrent forms of oxycodone drug products, Pisgah Laboratories, Inc. (www.pisgahlabs.com) achieves another technical milestone which may radically alter the landscape for pain medication regulations. Recently, the FDA ruled that the Abbreviated New Drug Applications (ANDAs) -- competitive to Purdue Pharma's branded Oxycodone® -- would no longer be considered if they...

Healthy test subjects with amyloid plaque were also found to have hypometabolism indicating a potential Alzheimer’s precursor Alzheimer’s disease has been linked in many studies to amyloid plaque buildup in the brain, but new research is finding a common thread between amyloid burden and lower energy levels, or metabolism, of neurons in certain areas of the brain associated with Alzheimer’s disease—even for people with no sign of cognitive decline. This is a new development in the...

New findings provide vital step towards exploring pain medications that may lower risks of prescription drug abuse and side effects of painkillers For patients managing cancer and other chronic health issues, painkillers such as morphine and Vicodin are often essential for pain relief. The body's natural tendency to develop tolerance to these medications, however, often requires patients to take higher doses – increasing risks of harmful side effects and dependency. Now, new research...

NORTH LIBERTY, Iowa, June 11, 2013 /PRNewswire/ -- KemPharm, Inc., a clinical stage biopharmaceutical company focused on the discovery and development of new, safer therapies to treat pain, announced today that the United States Patent and Trademark Office (USPTO) issued U.S. Patent No. 8,461,137 to KemPharm for its patent application entitled, "Benzoic Acid, Benzoic Acid Derivatives and Heteroaryl Carboxylic Acid Conjugates of Hydrocodone, Prodrugs, Methods of Making and Use...